HBV

Hepatitis B virus

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

(5S,8R)-HBV-IN-10

Cat. No.: HY-145053A

(5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen **(HBsAg)** inhibitor (0.001 μM< EC_{50} ≤0.05 μM). From patent WO2021204258A1, compound 6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Tenofovir-d6

Cat. No.: HY-113904S

(Rac)-Tenofovir-d6 ((Rac)-GS 1278-d6) is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a **nucleotide reverse transcriptase** inhibitor to treat **HIV** and chronic Hepatitis B (**HBV**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

(S)-Tenofovir

((S)-GS 1278; (S)-PMPA; (S)-TDF)

Cat. No.: HY-W074930

(S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

4,5-Dicaffeoylquinic acid

(Isochlorogenic acid C)

Cat. No.: HY-N0058

4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) possesses potent hepatoprotective and anti-HBV effects. IC50 value: Target: Anti-hepatitis natural produce.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

4-Hydroxyacetophenone

(P-hydroxyacetophenone)

Cat. No.: HY-Y0073

4-Hydroxyacetophenone (P-hydroxyacetophenone) is a key hepatoprotective and choleretic compound in Artemisia capillaris and A. morrisonensis, also has an anti-hepatitis B virus effect and anti-inflammatory effect.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

AB-423

Cat. No.: HY-112142

AB-423 is an inhibitor of **HBV capsid** assembly, and potent inhibits HBV replication with EC_{50}/EC_{90} of 0.08-0.27 μM/0.33-1.32 μM in cells.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AB-729

Cat. No.: HY-132603

AB-729, a nucleoside analogue, is a RNA interference (**RNAi**). AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).

AB-729

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adefovir

(GS-0393; PMEA)

Cat. No.: HY-B1826

Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**. Adefovir has an IC_{50} of 0.7 μM against **HBV** in the HepG2.2.15 cell line.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Adefovir dipivoxil

(GS 0840)

Cat. No.: HY-B0255

Adefovir dipivoxil, an adenosine analogue, is an oral prodrug of the **nucleoside reverse transcriptase** inhibitor Adefovir. Adefovir dipivoxil inhibits both the wild type and **HBV** Lamivudine-resistant strains.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Adefovir-d4

(GS-0393-d4; PMEA-d4)

Cat. No.: HY-B1826S2

Adefovir-d4 (GS-0393-d4) is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Adefovir-d4 diphosphate triethylamine

Cat. No.: HY-B1826S1

Adefovir-d4 diphosphate triethylamine is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Adefovir-d4 phosphate triethylamine

Cat. No.: HY-B1826S

Adefovir-d4 phosphate triethylamine is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Alisol F

Cat. No.: HY-N0854

Alisol F is a triterpene isolated from Alisma orientalis, has immunosuppressive and anti-virus functions. Alisol F exhibits inhibitory activity in vitro on hepatitis B virus (HBV) surface antigen (HBsAg) secretion of the HepG2.2.15 cell line with an IC_{50} of 0.6 μM.



Purity: 96.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AT-130

Cat. No.: HY-100028

AT-130, a phenylpropenamide derivative, is a potent **hepatitis B virus (HBV)** replication non-nucleoside inhibitor. AT-130 inhibits the viral **DNA synthesis** with an EC_{50} of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZT triphosphate

(3'-Azido-3'-deoxythymidine-5'-triphosphate)

Cat. No.: HY-116364

AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) is a active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate exhibits antiretroviral activity and inhibits replication of **HIV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

AZT triphosphate TEA

(3'-Azido-3'-deoxythymidine-5'-triphosphate TEA)

Cat. No.: HY-116364A

AZT triphosphate TFA (3'-Azido-3'-deoxythymidine-5'-triphosphate TFA) is a active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate TFA exhibits antiretroviral activity and inhibits replication of **HIV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Azvudine

(RO-0622; FNC)

Cat. No.: HY-19314

Azvudine (RO-0622) is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**. Azvudine exerts highly potent inhibition on HIV-1 (EC_{50}s ranging from 0.03 to 6.92 nM) and HIV-2 (EC_{50}s ranging from 0.018 to 0.025 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azvudine hydrochloride

(RO-0622 hydrochloride; FNC hydrochloride)

Cat. No.: HY-19314A

Azvudine (RO-0622) hydrochloride is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BA-53038B

Cat. No.: HY-114314

BA-53038B is a **HBV core protein allosteric modulator (CpAM)**, binding to the HAP pocket and modulating HBV capsid assembly in a distinct manner, with an EC_{50} value of 3.32 μM.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BA38017

Cat. No.: HY-145871

BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits **HBV replication** with an EC_{50} of 0.20 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bay 41-4109

Cat. No.: HY-100029

BAY 41-4109 is a potent inhibitor of human hepatitis B virus (**HBV**) with an IC_{50} of 53 nM.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Bay 41-4109 (less active enantiomer)

Cat. No.: HY-100029B

Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (**HBV**) with an IC_{50} of 53 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bay 41-4109 racemate

Cat. No.: HY-100029A

BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (**HBV**) with an IC_{50} of 53 nM.



Purity: 97.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bersacapavir

(JNJ-6379; JNJ-56136379)

Cat. No.: HY-109168

Bersacapavir is a novel **Hepatitis B Virus** capsid assembly modulator.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Besifovir

(LB80331)

Cat. No.: HY-19447

Besifovir (LB80331), a parent drug converted by LB80380, further metabolizes to its active form, LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV) .



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Besifovir Dipivoxil maleate

(LB80380 maleate)

Cat. No.: HY-19447A

Besifovir Dipivoxil maleate (LB80380 maleate) is an oral prodrug of LB80317.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Bicyclol

(SY801)

Cat. No.: HY-B0766

Bicyclol(SY 801) is a anti-hepatitis drug. Target: HBV Oral administration of bicyclol normalized the elevated serum transaminases (ALT, AST) by approximately 50% in chronic viral hepatitis B and C, and also showed certain level of inhibiting HBV and HCV replication.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Bifendate

(DDB)

Cat. No.: HY-W018791

Bifendate (DDB) is a synthetic intermediate of Schisandrin C with anti-**HBV** efficacy in research of chronic hepatitis B.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Bifendate-d6

(DDB-d6)

Cat. No.: HY-W018791S

Bifendate-d6 (DDB-d6) is the deuterium labeled Bifendate. Bifendate (DDB) is a synthetic intermediate of Schisandrin C with anti-**HBV** efficacy in research of chronic hepatitis B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Catalpol

(Catalpinoside)

Cat. No.: HY-N0820

Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-**HBV** effects.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Cetylpyridinium chloride

Cat. No.: HY-B1464

Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-**HBV capsid assembly** inhibitor with an **IC_{50}** of 2.5 μM.

Purity: 99.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Chamaechromone

Cat. No.: HY-133721

Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses **anti-hepatitis B virus (HBV)** effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Clevudine

(L-FMAU)

Cat. No.: HY-13859

Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent **anti-HBV** activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the **polymerase**.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Doxorubicin

(Hydroxydaunorubicin)

Cat. No.: HY-15142A

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits **topoisomerase II** with an **IC_{50}** of 2.67 μM, thus stopping DNA replication.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Doxorubicin hydrochloride

(Hydroxydaunorubicin hydrochloride)

Cat. No.: HY-15142

Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human **DNA topoisomerase I** and **topoisomerase II** inhibitor with **IC_{50}**s of 0.8 μM and 2.67 μM, respectively.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Entecavir

(BMS200475; SQ34676)

Cat. No.: HY-13623

Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of **HBV**, with an **EC_{50}** of 3.75 nM in HepG2 cell.



Purity: 98.88%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Entecavir monohydrate

(BMS200475 monohydrate; SQ34676 monohydrate)

Cat. No.: HY-13623A

Entecavir monohydrate (BMS200475 monohydrate; SQ34676 monohydrate) is a potent and selective inhibitor of **HBV**, with an **EC_{50}** of 3.75 nM in HepG2 cell.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Entecavir-d2

(BMS200475-d2; SQ34676-d2)

Cat. No.: HY-13623S

Entecavir-d2 (BMS200475-d2) is the deuterium labeled Entecavir. Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of **HBV**, with an **EC_{50}** of 3.75 nM in HepG2 cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Evixapodlin

(PD-1/PD-L1-IN 7)

Cat. No.: HY-138407

Evixapodlin (PD-1/PD-L1-IN 7) is a **human PD-1/PD-L1 protein/protein interaction** inhibitor with an **IC_{50}** of 0.213 nM. Evixapodlin has anticancer and antiviral functions.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Firzacorvir

Cat. No.: HY-139574

Firzacorvir is a cyclic sulfamide compound and modulates **HBV** core protein. Firzacorvir has anti-HBV activity with **EC_{50}** < 1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FNC-TP

Cat. No.: HY-139262

FNC-TP is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

FNC-TP trisodium

Cat. No.: HY-139262A

FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-26

Cat. No.: HY-124614

GLP-26 is a **HBV** capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC_{50}=3 nM), and reduces cccDNA by >90% at 1 μM. GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools.



Purity: 98.13%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Glycosmisic acid

Cat. No.: HY-N8153

Glycosmisic acid, a natural compound, possesses **anti-HBV** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

HBF-0259

Cat. No.: HY-126970

HBF-0259 is a potent and selective inhibitor of **hepatitis B virus (HBV)** surface antigen (HBsAg) secretion, with an EC_{50} of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

HBV-IN-10

Cat. No.: HY-145053

HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen **(HBsAg)** inhibitor (0.001 μM< EC_{50} ≤0.05 μM). From patent WO2021204258A1, compound 6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-11

Cat. No.: HY-145055

HBV-IN-11 is a potent **HBsAg secretion** inhibitor with an EC_{50} of 0.46 μM (From patent WO2018085619A1, example 28).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-12

Cat. No.: HY-145059

HBV-IN-12 is a potent hepatitis B surface antigen **(HBsAg)** inhibitor (0.001 μM< EC_{50} ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μMEC_{50} ≤0.02 μM). From patent WO2021204252A1, compound 15.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-13

Cat. No.: HY-145060

HBV-IN-12 is a potent hepatitis B surface antigen **(HBsAg)** inhibitor. From patent WO2021204252A1, compound 1_B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-14

Cat. No.: HY-144045

HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (**cccDNA**). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-16

Cat. No.: HY-144047

HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (**cccDNA**). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-17

Cat. No.: HY-144320

HBV-IN-17 (compound 8) is a potent **HBV** capsid assembly modulator with an EC_{50} of 511 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-19

Cat. No.: HY-145713

HBV-IN-19 inhibits hepatitis B virus (**HBV**) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-19 TFA

Cat. No.: HY-145713A

HBV-IN-19 TFA inhibits hepatitis B virus (**HBV**) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-20

Cat. No.: HY-145872

HBV-IN-20 is a potent and oral active **HBV** inhibitor with an EC_{50} of 0.46 μM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-4

Cat. No.: HY-131343

HBV-IN-4, a phthalazinone derivative, is a potent and orally active **HBV DNA replication** inhibitor with an IC_{50} of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-**HBV** potencies.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HBV-IN-6

Cat. No.: HY-145049

HBV-IN-6 is a potent **HBV** inhibitor with an EC_{50} of 44 nM (WO2021213445A1, compound 3).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-7

Cat. No.: HY-145050

HBV-IN-7 is a potent **HBV** inhibitor with an EC_{50} of 7 nM (WO2021213445A1, compound 5).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-8

Cat. No.: HY-145051

HBV-IN-8 is a potent **HBV** inhibitor with an EC_{50} of 287.9 nM (WO2021213445A1, compound 13).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HBV-IN-9

Cat. No.: HY-145052

HBV-IN-9 is a potent **HBsAg** (HBV Surface antigen) inhibitor (IC_{50}=10 nM) and **HBV DNA production** inhibitor (IC_{50}=0.15 nM in HepG2.2.15 cells). From patent WO2018001952A1, example 20.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Helioxanthin 8-1

(Helioxanthin analogue 8-1) **Cat. No.:** HY-16680

Helioxanthin 8-1 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 uM.



Purity: 97.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Helioxanthin derivative 5-4-2

(Helioxanthin 5-4-2) **Cat. No.:** HY-16679

Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.08 uM in HepG2.2.15 cells.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Hepatitis B Virus Core (128-140)

Cat. No.: HY-P1774

Hepatitis B Virus Core (128-140) is a peptide of hepatitis B virus core protein.

TPPAYRPPNAPIL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Inarigivir

(ORI-9020; SB-9000) **Cat. No.:** HY-101954

Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liver **HBV** DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as a **RIG-I** agonist to activate cellular innate immune responses.



Purity: 99.20%
Clinical Data: Phase 2
Size: 5 mg

Inarigivir ammonium

(ORI-9020 ammonium; SB-9000 ammonium) **Cat. No.:** HY-101954A

Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver **HBV** DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a **RIG-I (Retinoic acid-inducible gene-I)** agonist to activate cellular innate immune responses.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Inarigivir soproxil

(SB9200; GS-9992) **Cat. No.:** HY-109035

Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant **HCV** variants, with EC_{50}s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.



Purity: 99.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IR415

Cat. No.: HY-116999

IR415 is a potent **anti-HBV agent** and inhibits **HBV replication** by blocking the HBx activity. IR415 selectively interacts with **HBx** (K_d=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Isochlorogenic acid A

(3,5-Dicaffeoylquinic acid; 3,5-CQA) **Cat. No.:** HY-N0056

Isochlorogenic acid A (3,5-Dicaffeoylquinic acid) is a natural phenolic acid with antioxidant and anti-inflammatory activities .



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Isoscopoletin

(6-Hydroxy-7-methoxycoumarin) **Cat. No.:** HY-N1365

Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active constituent in Artemisia argyi leaves.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JNJ-632

Cat. No.: HY-112564

JNJ-632 is a hepatitis B virus (**HBV**) capsid assembly modulator (**CAM**).



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lagociclovir

(MIV-210) Cat. No.: HY-14844

Lagociclovir(MIV-210) is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LB80317

Cat. No.: HY-106235

LB80317 is an active metabolite of LB80380 and suppresses the **DNA synthesis** of **HBV** with an EC_{50} of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LPRP-Et-97543

Cat. No.: HY-N8168

LPRP-Et-97543 is a potent **anti-HBV** agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Merimepodib

(VX-497; MMPD) Cat. No.: HY-13986

Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (**IMPDH**) with broad spectrum antiviral activities.



Purity: 98.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Morphothiadin

(GLS4) Cat. No.: HY-108917

Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir-resistant **HBV** with an IC_{50} of 12 nM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mulberrofuran G

Cat. No.: HY-N3239

Mulberrofuran G protects ischemic injury-induced cell death via inhibition of **NOX4**-mediated ROS generation and ER stress. Mulberrofuran G shows moderate inhibiting activity of **hepatitis B virus (HBV)** DNA replication with the <b.



Purity: 96.42%
Clinical Data: No Development Reported
Size: 5 mg

NVR 3-778

Cat. No.: HY-124600

NVR 3-778 is a first-in-Class and oral bioavailable **HBV CAM** (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Osalmid

(Oxaphenamide; 4'-Hydroxysalicylanilide) Cat. No.: HY-B2116

Osalmid is a ribonucleotide reductase small subunit M2 (**RRM2**) targeting compound; suppresses ribonucleotide reductase activity with an IC_{50} of 8.23 μM.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

OSS_128167

Cat. No.: HY-107454

OSS_128167 is a potent selective **sirtuin 6 (SIRT6)** inhibitor with IC_{50}s of 89 μM, 1578 μM and 751 μM for **SIRT6**, SIRT1 and SIRT2, respectively. OSS_128167 has anti-**HBV** activity that inhibits **HBV** transcription and replication.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Osthole

(Osthol; NSC 31868) Cat. No.: HY-N0054

Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of **histamine H_1 receptor** activity. Osthole also suppresses the secretion of **HBV** in cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 1 g, 5 g

Oxethazaine

(Oxetacaine)

Cat. No.: HY-B0955

Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active **analgesic agent**. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Oxethazaine-d6

Cat. No.: HY-B0955S

Oxethazaine-d6 (Oxetacaine-d6) is the deuterium labeled Oxethazaine. Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active **analgesic agent**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Paederoside

Cat. No.: HY-N2432

Paederoside is a monoterpene S-methyl thiocarbonate isolated from Paederia pertomentosa. Paederoside shows a high anti-tumor promoting activity against the **Epstein-Barr virus** activation.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pseudolaric Acid B

Cat. No.: HY-N6939

Pseudolaric Acid B is a diterpene isolated from the root of Pseudolarix kaempferi Gorden (pinaceae), has anti-cancer, antifungal, and antifertile activities, and shows immunosuppressive activity on T lymphocytes.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Punicalagin

Cat. No.: HY-N0063

Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive **3CL^{pro}** inhibitor and inhibits **SARS-CoV-2** replication in vitro.



Purity: 99.90%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 20 mg

Punicalin

Cat. No.: HY-N0639

Punicalin is a hydrolyzable tannin isolated from Punica granatum L. or the leaves of Terminalia catappa L.. Punicalin is a anti-**hepatitis B virus (HBV)** agent and has anti-inflammatory activity.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

RG7834

(RO 7020322)

Cat. No.: HY-117650A

RG7834 (RO 7020322) is a highly selective and orally bioavailable **HBV** inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC_{50}s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.



Purity: 99.46%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RIG-1 modulator 1

Cat. No.: HY-107902

RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including **influenza virus**, **HBV**, **HCV** and **HIV** extracted from patent WO 2015172099 A1.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

RO6889678

Cat. No.: HY-124364

RO6889678 is a highly potent **HBV** capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO8191

(CDM-3008; RO4948191)

Cat. No.: HY-W063968

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent **interferon (IFN) receptor** agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and **JAK/STAT** phosphorylation.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Schisantherin C

Cat. No.: HY-123336

Schisantherin C exhibits anti-**HBV** activity with potency against HBsAg and HBeAg secretion by 59.7% and 34.7% at 50μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Schisanwilsonin C

(Arisanschinin K)

Cat. No.: HY-N2988

Schisanwilsonin C (Arisanschinin K) shows anti-HBV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Selgantolimod

(GS-9688)

Cat. No.: HY-109137

Selgantolimod (GS-9688) is an orally active, potent and selective **toll-like receptor 8 (TLR8)** agonist for the treatment of **hepatitis B virus (HBV)** and human immunodeficiency virus (HIV) infection.



Purity: 99.17%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

SHR5133

Cat. No.: HY-144319

SHR5133 is a highly potent, orally active **HBV capsid assembly** modulator. SHR5133 displays HBV DNA reduction (EC_{50}=26.6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sophoranol

Cat. No.: HY-126033

Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-**HBV (hepatitis B virus)** activity. Sophoranol shows potent antiviral activities against **respiratory syncytial virus (RSV)** with an IC_{50} of 10.4 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Squalamine

(MSI-1256)

Cat. No.: HY-16468

Squalamine(MSI-1256) is an aminosterol compound with potent broad spectrum antiviral activity.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 50 mg

Swertianolin

Cat. No.: HY-N2192

Swertianolin, a xanthone isolated from Gentianella Acuta, inhibits **acetylcholinesterase (AChE)**. Swertianolin also exhibits anti-HBV and anti-bacterial activity.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taribavirin

Cat. No.: HY-10545

Taribavirin is an orally active **inosine monophosphate dehydrogenase** inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taribavirin hydrochloride

Cat. No.: HY-10545A

Taribavirin hydrochloride is an orally active **inosine monophosphate dehydrogenase** inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 1 mg

Telbivudine

(Epavudine; L-Thymidine; NV 02B)

Cat. No.: HY-B0017

Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus **(HBV)** replication.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Telbivudine-d4

(Epavudine-d4; L-Thymidine-d4; NV 02B-d4) Cat. No.: HY-B0017S

Telbivudine-d4 is deuterium labeled Telbivudine. Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenofovir

(GS 1278; PMPA) Cat. No.: HY-13910

Tenofovir (GS 1278) is a **nucleotide reverse transcriptase** inhibitor to treat **HIV** and chronic Hepatitis B (**HBV**).



Purity: 99.81%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir amibufenamide

(HS-10234) Cat. No.: HY-137453

Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits **HBV**, and can be used for chronic hepatitis B (CHB) study.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tenofovir Disoproxil

(Bis(POC)-PMPA; GS 4331) Cat. No.: HY-13782A

Tenofovir Disoproxil (Bis(POC)-PMPA) is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tenofovir Disoproxil fumarate

(Tenofovir DF; Bis(POC)-PMPA fumarate; GS 4331 fumarate) Cat. No.: HY-13782

Tenofovir Disoproxil fumarate is a **nucleotide reverse transcriptase** inhibitor used to treat **HIV** and chronic **Hepatitis B**.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tenofovir exalidex

(CMX-157) Cat. No.: HY-109014

Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant **HIV** strains, including multidrug nucleoside/nucleotide analog-resistant viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thiamine hydrochloride (Thiamine chloride hydrochloride; Vitamin B1 hydrochloride)

Cat. No.: HY-N0680

Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient needed as a cofactor for many central metabolic enzymes.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

Thiamine monochloride-C13 hydrochloride

Cat. No.: HY-N0680S

Thiamine monochloride-C13 hydrochloride is the deuterium labeled Thiamine hydrochloride. Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient needed as a cofactor for many central metabolic enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thiamine-13C3 hydrochloride (Thiamine chloride-13C3 hydrochloride; Vitamin B1-13C3 hydrochloride)

Cat. No.: HY-N0680S3

Thiamine-13C3 (Thiamine chloride-13C3) hydrochloride is the 13C-labeled Thiamine (hydrochloride). Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient needed as a cofactor for many central metabolic enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thiamine-d3 hydrochloride (Thiamine chloride-d3 hydrochloride; Vitamin B1-d3 hydrochloride)

Cat. No.: HY-N0680S1

Thiamine-d3 (Thiamine chloride-d3) hydrochloride is the deuterium labeled Thiamine hydrochloride. Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient needed as a cofactor for many central metabolic enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thiamine-d4 hydrochloride (Thiamine chloride-d4 hydrochloride; Vitamin B1-d4 hydrochloride)

Cat. No.: HY-N0680S2

Thiamine-d4 (hydrochloride) is deuterium labeled Thiamine (hydrochloride). Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient needed as a cofactor for many central metabolic enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLR8 agonist 4

Cat. No.: HY-144215

TLR8 agonist 4 showed effective inhibition on wild-type and drug-resistant (lamivudine and entecavir) HBV strains. The IC_{50} values are 0.15 and 0.10 respectively μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Torcitabine (2'-Deoxy-L-cytidine)

Cat. No.: HY-121513

Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg

Vebicorvir (ABI-H0731)

Cat. No.: HY-109195

Vebicorvir (ABI-H0731) is a first-generation **hepatitis B virus (HBV) core protein** inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC_{50}s from 1.84μM to 7.3μM.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vesatolimod (GS-9620)

Cat. No.: HY-15601

Vesatolimod (GS-9620) is a potent, selective and orally active agonist of **Toll-Like Receptor (TLR7)** with an EC_{50} of 291 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vonafexor (EYP001)

Cat. No.: HY-109197

Vonafexor (EYP001) is a selective **FXR** agonist with anti-HBV effects.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg